Supposedly its different as in it doesn’t work on D2 receptors maybe a different side effect profile? Might help alot with negatives
1 Like
I read about it but it has side effects and a lot of meds fail final clinical trials for negative symptoms, there is also KarXT:
“Some adverse events reported in preliminary clinical trials are somnolence, agitation, nausea, diarrhea, and dyspepsia”
1 Like
Does KarXT work differently than regular antipsychotics?
Yes, it works on muscarinic acetylcholine receptors:
“Xanomeline ( LY-246,708 ; Lumeron , Memcor ) is a muscarinic acetylcholine receptor agonist with reasonable selectivity for the M1 and M4 subtypes, though it is also known to act as a M5 receptor antagonist. It has been studied for the treatment of both Alzheimer’s disease and schizophrenia, particularly the cognitive and negative symptoms”
1 Like
First clinical trial it caused gastrointestinal problems but this was fixed in the second trial by adding Tropsium to the main drug Xanomeline.
Second trials have no gastrointestinal problems.
2 Likes
It seems to still cause nausea and dyspepsia though doesn’t it?
That’s in the first trial without Tropsium. Its bcz Xanomeline also acted outside the brain on the spinal cord but the added Tropsium blocks the effects of Xanomeline outside the brain now in KarXT.
3 Likes
Here is the company website:
1 Like
Do you know when they will begin phase 3 trials?
“One additional Phase 3 trial, along with previously completed Phase 2 trial, would be acceptable to support an efficacy claim for a New Drug Application filing
Company on track to initiate Phase 3 program, including efficacy and open-label long-term safety trials, by the end of 2020”
2 Likes
This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.